Castle Biosciences Advances Barrett’s Risk Testing With TissueCypher
Friendswood, Texas, U.S., September 28, 2026 Castle Biosciences has announced new clinical evidence demonstrating how its TissueCypher® Barrett’s Esophagus...
Gastroenterology
Advertisement
Palisade Bio Gains FDA IND Clearance for PALI-2108
DENVER, Colo. — September 22, 2026 Palisade Bio announced that the U.S. Food and Drug Administration has cleared the...
HFSA Highlights Late-Breaking Heart Failure Clinical Research
Washington, D.C., September 20, 2026 The Heart Failure Society of America (HFSA) has announced the late-breaking clinical research program...
Accro Bioscience Advances AC-101 in Ulcerative Colitis
New York, United States, September 20, 2026 Accro Bioscience has announced that the first patient has been dosed in...
Debut Develops Biotech Ingredient for Hyperpigmentation Care
San Francisco, California, September 15, 2026 Debut has announced the development of a new biotechnology-derived ingredient for hyperpigmentation, marking...
Advertisements
Castle Biosciences Shows TissueCypher Improves Barrett’s Care
Phoenix, Arizona, September 15, 2026 Castle Biosciences has announced findings from a new decision-modeling study showing that its TissueCypher...
Can-Fite Reports Namodenoson Liver Cirrhosis Case
RAMAT GAN, Israel — September 9, 2026 Can-Fite BioPharma Ltd. announced publication of a peer-reviewed case report describing clinical...
Amgen and AstraZeneca Report Positive Phase 3 EoE Data
Thousand Oaks, California, United States, Aug. 27, 2026 Amgen and AstraZeneca have announced positive top-line results from the Phase...
AbbVie Submits SKYRIZI SC Induction Application to EMA
North Chicago, Illinois, United States, Aug. 27, 2026 AbbVie has submitted a regulatory application to the European Medicines Agency...
Tvardi Therapeutics Highlights TTI-109 Potential in Ulcerative Colitis
HOUSTON, Texas, August 12, 2026 Tvardi Therapeutics, Inc. announced that it will host a key opinion leader (KOL) webinar...
Advertisement
